Treating HCV in HIV 2013: On the cusp of change

Valérie Martel-Laferrière, Douglas T. Dieterich

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Treating hepatitis C virus (HCV) in HIV/HCV co-infected patients is a challenge. Even if the benefits of achieving a sustained virological response are clear, the rates achieved with the combination of pegylated-interferon and ribavirin are disappointing. The addition of direct acting antiviral agents (DAAs) to the treatment of hepatitis C is revolutionizing the treatment of HCV in mono-infected patients. Even if there have not been any agents approved for the treatment of co-infected patients, many studies specifically designed for this population are ongoing. This article reviews available data on the use of DAAs in co-infected patients and the challenges associated with these new drugs.

Original languageEnglish
Pages (from-to)53-59
Number of pages7
JournalLiver International
Issue numberSUPPL1
StatePublished - Feb 2014


  • Co-infection
  • Direct acting antiviral agents
  • HIV
  • Hepatitis C


Dive into the research topics of 'Treating HCV in HIV 2013: On the cusp of change'. Together they form a unique fingerprint.

Cite this